Relay Therapeutics, Inc. (NASDAQ: RLAY) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -3.89 | Insider Own | 22.10% | Shs Outstand | 219.14M | Perf Week | -0.16% |
| Market Cap | 4.13B | Forward P/E | - | EPS next Y | -1.62 | Insider Trans | -13.38% | Shs Float | 171.50M | Perf Month | -9.16% |
| Enterprise Value | 3.24B | PEG | - | EPS next Q | -0.40 | Inst Own | - | Short Float | 25.39% | Perf Quarter | 18.64% |
| Income | -276.00M | P/S | - | EPS this Y | 58.76% | Inst Trans | - | Short Ratio | 13.04 | Perf Half Y | 88.40% |
| Sales | 15.00M | P/B | 4.64 | EPS next Y | -0.73% | ROA | -29.57% | Short Interest | 43.55M | Perf YTD | 122.70% |
| Book/sh | 4.06 | P/C | 4.53 | EPS next 5Y | - | ROE | -42.27% | 52W High | 21.27 -11.42% | Perf Year | 360.64% |
| Cash/sh | 4.16 | P/FCF | - | EPS past 3/5Y | - | ROIC | -33.72% | 52W Low | 4.15 353.98% | Perf 3Y | 98.52% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 146.62% -28.98% | Gross Margin | -566.59% | Volatility | 3.10% 4.02% | Perf 5Y | -41.40% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | 33.47% | Oper. Margin | -2999.38% | ATR (14) | 0.82 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 18.27 | Sales Y/Y TTM | - | Profit Margin | -2763.64% | RSI (14) | 46.56 | Recom | 1.93 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.27 | EPS Q/Q | 0.00% | SMA20 | -1.17% | Beta | 1.66 | Target Price | 26.25 |
| Payout | 0.00% | Debt/Eq | 0.05 | Sales Q/Q | -100.00% | SMA50 | -2.46% | Rel Volume | 3.17 | Prev Close | 19.19 |
| Employees | 202 | LT Debt/Eq | 0.05 | Earnings | Nov 05 | SMA200 | 39.69% | Avg Volume | 3.18M | Price | 18.84 |
| IPO Date | Jul 16, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -4.84% -63.54% | Net Debt/EBITDA | 0.32 | Volume | 10,076,057 | Change | -1.82% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-20-26 | Reiterated | HC Wainwright & Co. | Buy | $28 → $29 |
| Aug-07-26 | Reiterated | Barclays | Overweight | $27 → $30 |
| Jul-21-26 | Reiterated | Goldman Sachs | Buy | $22 → $31 |
| Jul-16-26 | Initiated | Canaccord | Buy | $29 |
| May-26-26 | Reiterated | Guggenheim | Buy | $22 → $26 |
| May-26-26 | Reiterated | HC Wainwright & Co. | Buy | $25 → $28 |
| May-20-26 | Reiterated | Barclays | Overweight | $17 → $27 |
| May-19-26 | Reiterated | UBS | $23 → $26 | |
| Apr-29-26 | Reiterated | HC Wainwright & Co. | Buy | $19 → $25 |
| Apr-28-26 | Reiterated | Oppenheimer | Outperform | $14 → $18 |
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 15 | 10 | 26 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 4 | 315 | 326 | — | — | — | — | — | |
| Gross Profit | 12 | -305 | -301 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 57 | 80 | 79 | — | — | — | — | — | |
| Research and Development | 261 | 319 | 330 | — | — | — | — | — | |
| Other Operating Expense | -3 | -332 | -337 | — | — | — | — | — | |
| Operating Income | -303 | -372 | -373 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 26 | 35 | 31 | — | — | — | — | — | |
| Net Income Before Taxes | -276 | -338 | -342 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -276 | -338 | -342 | — | — | — | — | — | |
| Net Income From Continuing Operations | -276 | -338 | -342 | — | — | — | — | — | |
| Net Income | -276 | -338 | -342 | — | — | — | — | — | |
| EPS (Recurring) | -1.61 | -2.36 | -2.79 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.61 | -2.36 | -2.79 | — | — | — | — | — | |
| EPS (Diluted) | -1.61 | -2.36 | -2.79 | — | — | — | — | — | |
| EBITDA | -273 | -380 | -374 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 97.01 | 58.92 | 52.09 | — | — | — | — | — | |
| Gross Margin | 80.00 | -3,050.00 | -1,157.69 | — | — | — | — | — | |
| Operating Margin | -2,020.00 | -3,720.00 | -1,434.62 | — | — | — | — | — | |
| Net Margin | -1,840.00 | -3,380.00 | -1,315.38 | — | — | — | — | — | |
| Shares Outstanding | 172 | 143 | 123 | — | — | — | — | — | |
| Market Capitalization | 1,455 | 589 | 1,354 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bergstrom Donald A | President, R&D | Sep 08 '26 | Sale | 18.97 | 8,530 | 161,814 | 399,130 | Sep 09 |
| Catinazzo Thomas | Chief Financial Officer | Sep 08 '26 | Sale | 18.94 | 17,717 | 335,560 | 122,851 | Sep 09 |
| Patel Sanjiv | President and CEO | Sep 08 '26 | Sale | 18.94 | 48,199 | 912,889 | 519,500 | Sep 09 |
| Rahmer Peter | See remarks | Aug 26 '26 | Sale | 20.03 | 4,508 | 90,295 | 223,657 | Aug 28 |
| SVF Pauling (Cayman) Ltd | 10% Owner | Aug 25 '26 | Sale | 19.40 | 6,000,000 | 116,400,000 | 21,904,963 | Aug 28 |
| Patel Sanjiv | President and CEO | Aug 17 '26 | Sale | 20.33 | 48,199 | 979,886 | 567,699 | Aug 18 |
| Catinazzo Thomas | Chief Financial Officer | Aug 14 '26 | Sale | 19.74 | 17,717 | 349,734 | 140,568 | Aug 18 |
| Bergstrom Donald A | President, R&D | Jul 28 '26 | Sale | 18.61 | 2,237 | 41,631 | 407,660 | Jul 30 |
| Catinazzo Thomas | Chief Financial Officer | Jul 28 '26 | Sale | 18.61 | 1,459 | 27,152 | 158,285 | Jul 30 |
| Rahmer Peter | See remarks | Jul 28 '26 | Sale | 18.61 | 748 | 13,920 | 228,165 | Jul 30 |
| Patel Sanjiv | President and CEO | Jul 07 '26 | Sale | 19.58 | 48,199 | 943,736 | 615,898 | Jul 08 |
| Bergstrom Donald A | President, R&D | Jul 06 '26 | Sale | 18.71 | 8,660 | 162,029 | 409,897 | Jul 08 |
| Catinazzo Thomas | Chief Financial Officer | Jul 06 '26 | Sale | 18.69 | 17,717 | 331,131 | 159,744 | Jul 08 |
| Rahmer Peter | See remarks | Jun 30 '26 | Sale | 19.09 | 50,000 | 954,500 | 225,857 | Jul 02 |
| Catinazzo Thomas | Chief Financial Officer | Jun 22 '26 | Option Exercise | 4.93 | 169,446 | 834,669 | 239,024 | Jun 24 |